Compare NetApp Inc. (NTAP) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetApp Inc. vs Novavax Inc — how do they compare? NetApp Inc. trades at $231.47 (market cap $45.38B), while Novavax Inc trades at $12.16 (market cap $1.82B). The key difference: NetApp Inc. is far larger — about 24.9× Novavax Inc's market cap, and NetApp Inc. pays a 0.9% dividend while Novavax Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold NetApp Inc. for 57 Days and Novavax Inc for 59 Days on average.
| NTAP | NVAX | |
|---|---|---|
Market Cap | $45.38B | $1.82B |
Volume | 2,264,311 | 6,198,505 |
Sector | Technology | Health |
52-Week High | $235.84 | $12.56 |
52-Week Low | $94.11 | $6.22 |
Typical Hold Time | 57 Days | 59 Days |
Enterprise Value | $44.34B | $1.39B |
Dividend Yield | 0.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NetApp (NTAP) trades at $235.84, up 3.23% today and approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and recent earnings beats. Fundamentally, the company maintains robust profitability with 70.63% gross margins and 19.19% net income margin. Recent AI infrastructure partnerships with Oracle, SAP, and Supermicro position NTAP for growth in the expanding AI data storage market.
Outlook remains positive with AI-driven demand creating new revenue opportunities, though valuation multiples appear elevated. Key risks include competitive pressures in cloud storage and potential market volatility. Analyst consensus leans neutral with 50.7% hold ratings, suggesting cautious optimism amid strong technical performance.
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong revenue of $1.12 billion in 2025 and a net income of $440.30 million, but faces negative cash flow and a projected net loss for 2026. Recent news highlights its strategic pivot to a partnership-driven model using its Matrix-M adjuvant technology, with regulatory approvals for its updated COVID-19 vaccine in key markets.
The outlook for NVAX is mixed, with analyst consensus strongly favoring a buy rating (73.92%) but significant financial risks including negative equity, persistent cash burn, and volatile earnings. Investment opportunity lies in the successful execution of its licensing strategy and expansion into oncology, though execution risks and competitive pressures remain key concerns for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
